Message from the Chair: Remembering Pharma’s “Why”
Remembering the “why” of our pharma industry is so important and, for me, also very personal. My sister Linda was 69 and her four grandchildren were the light of her life. In November 2017, she was diagnosed with appendix cancer (a rare cancer, closely related to colon cancer). After four months of nasty chemotherapy, Linda entered hospice care and died the next month. Previously, my mother passed due to colon cancer, a mere 18 days following her diagnosis. It is these tragic losses, and similar stories of so many others, that remind me just how much work is yet to be done.